Skip to main content

Table 1 Baseline characteristics

From: Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification

 

B1

N = 123 (32.5)

B2

N = 225 (59.5)

B3

N = 30 (8.0)

Age (years)

70 (45–93)

70 (26–93)

68 (50–86)

Sex

 Male

104 (84.5)

175 (77.8)

22 (73.3)

 Female

19 (15.5)

50 (22.2)

8 (26.7)

HBV positive

16 (13.1)

40 (17.8)

6 (20.7)

HCV positive

81 (65.8)

105 (46.7)

12 (42.9)

Plt (× 104/mm3)

11.5 (3.3–189)

14.3 (3.7–222)

10.7 (4.9–94.3)

PT (%)

83 (24–112)

86 (14–139)

64 (37–101)

T-Bil (mg/dL)

0.9 (0.3–2.8)

0.8 (0.3–2.5)

1.6 (0.3–3.2)

AST (IU/L)

41 (17–568)

50 (13–432)

45 (16–296)

ALT (IU/L)

37 (11–834)

41 (10–388)

33 (11–204)

Alb (g/dL)

3.9 (2.8–5.2)

3.8 (0.2–5.1)

2.7 (2.0–3.5)

ICGR15 (%)

20 (2.6–79.2)

16.5 (1.0–79.1)

39.0 (6.6–76.9)

AFP (ng/mL)

19.8 (0.5–8390)

34.3 (0.5–449,860)

60.8 (0.5–25,910)

DCP (mAU/mL)

79.5 (10–32,365)

345.5 (1.6–529,200)

333.5 (10–4,673,500)

Child-Pugh

 A

107 (87.0)

195 (86.7)

0 (0)

 B

16 (13.0)

30 (13.3)

30 (100.0)

Up to seven

 In

123 (100)

–

10 (33.3)

 Out

–

225 (100)

20 (66.7)

Tumor number

2 (2–5)

5 (2–20)

3 (2–15)

Tumor size (mm)

35 (7–50)

50 (8–355)

50 (13–200)

Treatment modalities

 Resection

70 (56.9)

88 (39.1)

6 (20.0)

 TACE

49 (39.8)

125 (55.6)

18 (60.0)

 Ablation

4 (3.0)

–

–

 HAIC

–

9 (4.0)

2 (6.7)

 Systemic chemotherapy

–

3 (1.3)

–

 Transplantation

–

–

1 (0.3)

 BSC

–

–

3 (10.0)

  1. AFP alpha-fetoprotein, Alb albumin, AST asparate aminotransferase, ALT alanine aminotransferase, BSC best supportive care, DCP des-gamma-carboxyprothorombin, HAIC hepatic arterial infusion chemotherapy, HBV hepatitis B virus, HCV hepatitis C virus, ICGR15 indocyanine green retention rate at 15 min, Plt platelet count, PT prothrombin time, TACE transarterial chemoembolization, T. Bil total bilirubin